Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: The CoRisk Study
- This study is registered in ClinicalTrials.gov under the number NCT00878813.
- Conflict of interest: MK, MCC, BM, and PS received support from Thermo Fisher Scientific to attend meetings and fulfilled speaking engagements not related to the CoRisk study. BM serves as a consultant and receives research support from Thermo Fisher Scientific not related o this study. All other authors have no financial disclosure related to the present manuscript.
- Funding: The study was supported by an unrestricted research grant of: B•R•A•H•M•S Biomarkers Clinical Diagnostics Division, Thermo Fisher Scientific, Neuendorfstr. 25;16761 Hennigsdorf-Berlin Germany; Foundation of the Inselspital Bern (Switzerland); Foundation Scientia et Arte, Bern (Switzerland); De Quervain's Grant for young clinical investigators, Clinical Trials Unit, Bern (Switzerland) to GMDM. Career Development Grant from the Swiss National Science Foundation (SNF) to MK. All supporting entities will have no role in the collection, management, analysis, and interpretation of the data; or the preparation, or approval of the manuscript.
Correspondence: Marcel Arnold, Department of Neurology, Inselspital, University of Bern, Freiburgstrasse 10, CH-3010 Bern, Switzerland.
Copeptin independently predicts functional outcome and mortality at 90 days and one-year after ischemic stroke. In patients with transient ischemic attack, elevated copeptin values indicate an increased risk of further cerebrovascular events.
The Copeptin Risk Stratification (CoRisk) study aims to validate the predictive value of copeptin in patients with ischemic stroke and transient ischemic attack. In patients with ischemic stroke, the CoRisk study aims to further explore the effect of treatment (i.e. thrombolysis) on the predictive value of copeptin.
Prospective observational multicenter study analyzing three groups of patients, i.e. patients with ischemic stroke treated with and without thrombolysis and patients with transient ischemic attack.
Primary end-point: In patients with ischemic stroke, the primary end-point includes disability (modified Rankin scale from 3 to 5) and mortality (modified Rankin scale 6) at three-months after stroke. In patients with transient ischemic attack, the primary end-point is a recurrent ischemic cerebrovascular event (i.e. ischemic stroke or recurrent transient ischemic attack). Secondary end-point: In patients with ischemic stroke, the secondary end-points include in-house complications (i.e. symptomatic intracerebral hemorrhage, malignant edema, aspiration pneumonia or seizures during hospitalization, and in-house mortality).